Company
Headquarters: Sandy, UT, United States
$171.5 Million
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-à structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Rafarma Pharmaceuticals, Inc. (WY) has the following listings and related stock indices.
Stock: OTC: RAFA wb_incandescent